BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer

Laëtitia Le Pottier, Boutahar Bendaoud, Maryvonne Dueymes, Capucine Daridon, Pierre Youinou*, Yehuda Shoenfeld, Jacques Olivier Pers

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Intravenous immunoglobulin (IVIg) has been used to treat autoimmune diseases and lymphoid malignancies with some therapeutic effect. In both these pathological conditions, there is an overproduction of BAFF (for "B-cell-activating factor of the TNF family"), and APRIL (for "a proliferation-inducing ligand"). The presence of antibodies (Abs) with BAFF and APRIL specificities in IVIg preparations was investigated by enzyme-linked immunosorbent assay, and Western Blot analysis. Apoptosis was measured by the annexin-V binding method, and confirmed using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling technique. Nonglycosylated recombinant BAFF, glycosylated affinity-purified BAFF, and recombinant APRIL (but not TNFα), were recognized by certain IgG in IVIg, and their F(ab′)2 fragments. Steric hindrance prevented the antiapoptotic effects of BAFF on B-lymphocytes. This work documents the presence of anti-BAFF and anti-APRIL Abs in IVIg. These can functionally neutralize the role of BAFF in B-cell survival. These anti-BAFF IgG might amend deleterious effects of BAFF in B-cell-mediated autoimmune diseases.

Original languageEnglish
Pages (from-to)257-265
Number of pages9
JournalJournal of Clinical Immunology
Issue number3
StatePublished - May 2007
Externally publishedYes


  • Apoptosis
  • Autoimmune disease
  • B lymphocyte-stimulator (BLyS)
  • B-cell activating factor of the TNF family (BAFF)
  • Cancer
  • Intravenous immunoglobulin


Dive into the research topics of 'BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer'. Together they form a unique fingerprint.

Cite this